Search results
Showing 181 to 195 of 215 results for arthritis
Evidence-based recommendations on baricitinib (Olumiant) for treating severe alopecia areata in adults.
Evidence-based recommendations on automated ankle brachial pressure index measurement devices to detect peripheral arterial disease in people with leg ulcers.
Topical antimicrobial dressings for locally infected leg ulcers: late-stage assessment (HTG751)
Late stage assessment (LSA) guidance on topical antimicrobial dressings for locally infected leg ulcers.
View recommendations for HTG751Show all sections
This guidance has been updated and replaced by NICE technology appraisal guidance 375.
Eteplirsen for treating Duchenne muscular dystrophy [ID1003]
Discontinued Reference number: GID-HST10007
Total distal radioulnar joint replacement for symptomatic joint instability or arthritis (IPG595)
We have moved interventional procedures guidance 595 to become HealthTech guidance 451. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA711)
This guidance has been updated and replaced by NICE technology appraisal guidance TA815.
Discontinued Reference number: GID-TA10310
NICE has developed a Medtech Innovation Briefing (MIB) on the OSCAR 3 ultrasonic arthroplasty revision instrument for removing bone cement during prosthetic
This guidance has been updated and replaced by NICE guideline NG219.
Evidence-based recommendations on pembrolizumab (Keytruda) for treating metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency in adults.
This guidance has been updated and replaced by NICE technology appraisal guidance 375.
In development Reference number: GID-TA11352 Expected publication date: TBC
Robot-assisted surgery for orthopaedic procedures: early value assessment (HTG743)
Early value assessment (EVA) guidance on robot-assisted surgery for orthopaedic procedures.
Evidence-based recommendations on adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi) and infliximab (Remicade, Remsima, Inflectra). These drugs are for people with active ankylosing spondylitis or non-radiographic axial spondyloarthritis .